Jason M Parks

US Patent:

7626031, Dec 1, 2009

Filed:

Nov 14, 2003

Appl. No.:

10/533555

Inventors:

Wei Xu - Danville CA, US
Erick Wang Co - Redwood City CA, US
John M. Nuss - Danville CA, US
Moon Hwan Kim - Palo Alto CA, US
Rhett Ronald Klein - San Francisco CA, US
Donna Tra Le - San Jose CA, US
Amy Lew Tsuhako - Milpitas CA, US
Jason Jevious Parks - Sacramento CA, US
Zhaoyang Wen - San Francisco CA, US
Wei Cheng - San Jose CA, US

Assignee:

Symphony Evolution, Inc. - Rockville MD

International Classification:

C07D 401/00
A61K 31/445

US Classification:

546196, 514320

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

US Patent:

7977345, Jul 12, 2011

Filed:

Jul 1, 2005

Appl. No.:

11/571140

Inventors:

Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Lisa Esther Dalrymple - San Leandro CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Yong Wang - Foster City CA, US
Wie Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C07D 487/04
A61K 31/519
A61K 31/522

US Classification:

5142651, 544280, 544262, 544265, 5142621, 51426323, 5142633

Abstract:

A compound for modulating kinase activity according to Formula I,.

US Patent:

8013156, Sep 6, 2011

Filed:

Mar 19, 2004

Appl. No.:

10/549300

Inventors:

Lynne Canne Bannen - Pacifica CA, US
S. David Brown - San Carlos CA, US
Wei Cheng - South San Francisco CA, US
Vasu Jammalamadaka - Pleasanton CA, US
John M. Nuss - Danville CA, US
Morrison B. Mac - San Francisco CA, US
Jason Jevious Parks - Sacramento CA, US
Matthew A. Williams - San Mateo CA, US
Wei Xu - Danville CA, US
Atwood Kim Cheung - Cambridge MA, US
Lisa Esther Dalrymple - San Francisco CA, US
Sergey Epshteyn - Fremont CA, US
Mohamed Abdulkader Ibrahim - Mountain View CA, US
James William Leahy - San Leandro CA, US
Gary Lee Lewis - San Francisco CA, US
Robin Tammie Noguchi - San Bruno CA, US
Larry Wayne Mann - Richland MI, US
Brian Hugh Ridgway - Belmont CA, US
Joan C. Sangalang - Mountain View CA, US
Kevin Luke Schnepp - Elk Grove CA, US
Xian Shi - San Bruno CA, US
Richard George Khoury - Redwood City CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C07D 401/14
C07D 403/14
A61K 31/4425
A61K 31/495
A61K 31/506
A61P 19/02
A61P 35/00

US Classification:

544359, 544360, 544361, 544324, 544295, 546193, 540597, 540598, 51425213, 51425214, 51425301, 514275, 514318, 51421101

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.

US Patent:

8067436, Nov 29, 2011

Filed:

May 24, 2007

Appl. No.:

11/753514

Inventors:

Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - San Leandro CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Grace Mann - Brisbane CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Forster City CA, US
Wie Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/47
A61K 31/4709
A61K 31/517
A61K 31/5377

US Classification:

514312, 546153, 544119, 544287, 544363, 544128, 5142345, 5142352, 51425217, 51425307, 5142662, 51426622, 5142663

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

US Patent:

8076338, Dec 13, 2011

Filed:

Apr 22, 2005

Appl. No.:

11/568173

Inventors:

Neel K. Anand - Burlingame CA, US
Charles M. Blazey - San Francisco CA, US
Owen Joseph Bowles - Pacifica CA, US
Joerg Bussenius - Foster City CA, US
Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Baili Chen - Palo Alto CA, US
Erick Wang Co - San Diego CA, US
Simona Costanzo - Los Altos CA, US
Steven Charles Defina - Burlingame CA, US
Larisa Dubenko - San Francisco CA, US
Maurizio Franzini - San Francisco CA, US
Ping Huang - Mountain View CA, US
Vasu Jammalamadaka - Pleasonton CA, US
Richard George Khoury - Redwood City CA, US
Moon Hwan Kim - Palo Alto CA, US
Rhett Ronald Klein - Chicago IL, US
Donna Tra Le - San Jose CA, US
Morrison B. Mac - San Francisco CA, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Kenneth D. Rice - San Rafael CA, US
Tsze H. Tsang - El Cerrito CA, US
Amy Lew Tsuhako - Milpitas CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/501
A61K 31/497
C07D 473/16
C07D 401/04

US Classification:

51425202, 51425216, 544277, 544238, 544363

Abstract:

The present invention relates to compounds of the Formula (I) and (II) wherein R, R, R-R, m, n, X-X, and Qare defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

US Patent:

8178532, May 15, 2012

Filed:

May 24, 2007

Appl. No.:

11/753462

Inventors:

Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Yong Wang - Foster City CA, US
Wie Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/535
C07D 413/00

US Classification:

5142372, 5142345, 5142352, 544116, 544128

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

US Patent:

8476298, Jul 2, 2013

Filed:

May 24, 2007

Appl. No.:

11/753503

Inventors:

Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Jeff Chen - San Francisco CA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - Redwood City CA, US
James William Leahy - San Leandro CA, US
Morrisson B. Mac - San Francisco CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wie Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A01N 43/42
A61K 31/47
C07D 239/72

US Classification:

514312, 5142345, 5142355, 51426621, 51426631, 514307, 544116, 544128, 544284, 544287, 546146, 546156

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

US Patent:

8497284, Jul 30, 2013

Filed:

Sep 30, 2011

Appl. No.:

13/249815

Inventors:

Lynne Canne Bannen - Lucerne CA, US
Diva Sze-Ming Chan - Oakland CA, US
Jeff Chen - San Francisco CA, US
Lisa Esther Dalrymple - Seattle WA, US
Timothy Patrick Forsyth - Hayward CA, US
Tai Phat Huynh - Oakland CA, US
Vasu Jammalamadaka - Pleasanton CA, US
Richard George Khoury - San Mateo CA, US
James William Leahy - San Leandro CA, US
Morrison B. Mac - San Francisco CA, US
Grace Mann - San Mateo CA, US
Larry W. Mann - Richland MI, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Craig Stacy Takeuchi - Burlingame CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/47

US Classification:

514312, 546153

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.